Good afternoon, and welcome to the Accuray Q1 fiscal 2023 financial results conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing star, then zero on your telephone keypad. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your telephone keypad. To withdraw your question, please press star, then two. Please note this event is being recorded. I would now like to turn the conference over to Ken Mobeck, Accuray Vice President, Finance. Please go ahead. Thank you, operator, and good afternoon, everyone. Welcome to Accuray's conference call to review financial results for the Q1 of fiscal year 2023, which ended September 30 2022. During our call this afternoon, management will review recent corporate developments. Joining us on today's call are Suzanne Winter, Accuray's President and Chief Executive Officer, and Ali Pervaiz, Accuray's Chief Financial Officer. Before we begin, I would like to remind you that our call today includes forward-looking statements. Actual results may differ materially from those contemplated or implied by these forward-looking statements. Factors that could cause these results to differ materially are set forth in the press release we issued just after the market closed this afternoon, as well as in our filings with the Securities and Exchange Commission. The forward-looking statements on this call are based on information available to us as of today's date, and we assume no obligation to update any forward-looking statements as a result of new information or future events, except to the extent required by applicable securities laws. Accordingly, you should not put undue reliance on any forward-looking statements. A few housekeeping items for today's call. First, during the Q&A session, we request that participants limit themselves to two questions and then re-queue with any follow-ups. Second, all references we make to a specific quarter in the prepared remarks are to our fiscal year quarters. For example, statements regarding our Q1 refer to our fiscal Q1 ended September 30 2022. Additionally, there will be a supplemental slide deck to accompany this call, which can be accessed by going directly to Accuray's investor page at investors.accuray.com. With that, let me turn the call over to Accuray's Chief Executive Officer, Suzanne Winter. Suzanne? Thank you, Ken. Good afternoon, and thank you for joining the call. I am proud of how the Accuray team delivered a solid Q1 of the fiscal year, despite the challenging macroeconomic operating environment. As such, we are reiterating fiscal year guidance on revenue and EBITDA. I'll start this afternoon with a reminder of the long-term plan we laid out at the end of fiscal 2022, focused on growing our business faster than the market by delivering differentiated solutions to improve care and outcomes for all stakeholders, growing and improving our service business offering, and finally, enhancing margins and cash flow. In fiscal Q1, we have made significant progress in advancing that growth strategy. In the quarter, we introduced new innovative solutions from our investments in R&D, and we continue to execute on our commitment to delivering a robust product pipeline of differentiated solutions which will deliver revenue, share growth, and shareholder value over the next several years. While we are early in the execution of our plan, we are already starting to see the impact. We recently attended the ASTRO show in San Antonio, Texas, where it was wonderful to see the radiation oncology community getting nearly back to pre-COVID level attendance and evaluating new technology. At the show, we launched VitalHold, an integrated and automated surface-guided radiotherapy solution for breast cancer patients on the Radixact System. This development was the achievement of our partnership with C-RAD. VitalHold, in addition to Synchrony adaptive delivery and ClearRT helical ultra-high quality imaging, provides Radixact customers with the most comprehensive tool set to treat breast cancer. This is important because one in eight women will be diagnosed with breast cancer in their lifetime, and as a result, breast cancer represents one of the highest procedure volumes in a typical radiation therapy department. Additionally, at ASTRO, we demonstrated our newest innovation, ARTemis, the online adaptive capability in partnership with RaySearch, a leader in treatment planning and OIS systems. ARTemis uses Radixact's ClearRT helical CT images with RaySearch's AI-powered algorithms to adapt the treatment plan to changes in the patient's condition that can occur between treatment appointments. ARTemis, in combination with Accuray's proprietary Synchrony technology that corrects for changes during treatment delivery, represents a powerful competitive advantage for Accuray and will be a critical tool for the delivery of shorter regimen treatments that deliver a treatment dose over five or less fractions. As we execute our growth strategy, we've placed a high priority on key industry partnerships such as C-RAD, RaySearch, Brainlab, Limbus AI, all of which have substantially broadened our markets and have enabled us to provide best-in-class solutions to key medical centers globally. Earlier this month, we announced a new global commercial partnership with GE Healthcare. GE Healthcare, a global innovation leader with a strategic focus on personalized oncology solutions, chose Accuray because of its strong brand and leadership in precision radiotherapy. The agreement will allow both companies to advance personalized cancer care and offer solutions throughout the care pathway from precision diagnostics, precision treatment delivery and planning, to precision monitoring post-treatment. Our joint goal is to leverage the expertise, commercial footprint, and best-in-class technologies of both companies to advance care, expand global reach, and reduce the time between cancer detection and treatment. At ASTRO, we held a clinical session for analysts and investors where key U.S. opinion leaders discussed innovation and the future of radiotherapy. At the session, we announced support for clinical evidence generation that will help in three significant ways. One, driving the adoption of SBRT and SRS into clinical practice. Two, demonstrating the impact of Accuray technology. Finally, generate clinical data to assist with reimbursement. Key opinion leaders discussed plans for clinical registries using Accuray technology in prostate cancer, breast cancer, and in neurofunctional care. For the quarter, we delivered $96.5 million in revenue, driven by strong demand in Japan and EMEA. Revenue for the quarter reflected a 10.5% increase in units year-over-year. We were unable to recognize three planned system shipments due to delivery delays of critical subcomponents from a few suppliers. While supply chain conditions have generally improved, we continue to navigate and actively support a few key suppliers. However, our teams understand the issues and are proactively addressing short, mid, and long-term solutions until conditions improve. Additionally, as expected, China revenue was a headwind, down 55% year-over-year, primarily due to the impact of their Zero-COVID policy. Despite the macro headwind, underlying customer demand is strong. This is evidenced by improving demand trends we are seeing in orders. We booked 32 new system orders for Radixact and the CyberKnife S7, driven by the Americas and APAC region. Reported orders growth overall was flat, but grew approximately 6.5% once adjusted for FX, compared to the extraordinary quarter last year, which grew approximately 38% due to pent-up demand following COVID. We continue to be encouraged by the commercial traction of new innovations like ClearRT, Synchrony, and VOLO Ultra that are driving our trade-in trade-up win rates and capturing competitive bunkers as 22% of our system orders came from displacing competitive systems. Despite the impact on revenue in China due to their COVID lockdowns, we are encouraged to see signs of improved performance within the China market. The China region orders grew 33% year-over-year, lifted by wins with our current product in the Type B segment. In the Type A segment, we were pleased to see the reactivation of the Type A bidding after a long delay. Customers that were holding Type A licenses for the second round of bidding have successfully initiated their bidding processes, allowing them to begin installation planning, including 18 Accuray systems, which we expect to see delivered over the first three quarters of the calendar year 2023. Finally, I am pleased with the significant progress our regulatory and operations teams have made to advance our JV Type B product toward market clearance. I am pleased to announce that all product testing has been completed and our NMPA regulatory submission has been received by the agency one month ahead of expectation and is formally in process for review. Our JV partners are initiating targeted market introductions with a full launch beginning in the spring of calendar year 2023. We continue to make progress on our service growth agenda. This will be a transformational journey for our service business over the next several years, and we are already beginning to see improvements in service margin and expect to announce new service and support solutions in the second half of 2023. Finally, our margin and profitability expansion plans have been activated. We have identified three pillars for our focus. First, pricing discipline to capture higher value for our innovation. Second, reducing our product and service costs. And lastly, optimizing our operating expenses. Ali will speak more about our margin and profitability execution plan. Overall, I am pleased with the performance of our teams within the quarter, and I will now turn it over to Ali to discuss the financials. Thank you, Suzanne, and good afternoon, everyone. I'd like to start by thanking our global cross-functional teams who executed with dedication to deliver a solid Q1 of fiscal 2023. Despite ongoing challenges, including supply chain shortages, the COVID-19 lockdown in China, the war in Ukraine, global inflationary pressure, and FX headwinds in our non-U.S. markets, total revenue for the Q1 was $96.5 million, which was down 10% compared to the prior fiscal year, mainly driven by supply chain constraints and a $5.8 million foreign exchange headwind on a constant currency basis. Product revenue for the Q1 was $44.6 million, which was down 13.4% from prior year and down 11.4% once adjusted for the impact of FX compared to tough comparisons in Q1 last year when product revenues grew 69% due to pent-up demand after COVID delays. We were unable to ship three planned units in the quarter, representing approximately $6 million due to last-minute shortages for critical components, but were able to fulfill our customers' demand in early October. Service revenue for the quarter was $51.9 million, which was down 5% from prior year, but up 1.7% once adjusted for the impact of FX, which had a $3.7 million impact. Gross orders for the Q1 were $69.8 million, which was flat from prior year and up 6.5% or $4.7 million once adjusted for the impact of FX. As discussed in our prior earnings call, our book-to-bill ratio, which is defined as gross orders divided by product revenue, was 1.6 in the Q1, which was at a healthy level compared to the industry standard of 1.2-1.3. We are making excellent progress and our teams continue to focus on booking orders that are expected to convert to revenue in a more time-efficient manner prior to 30 months. Moving to backlog. As a reminder, we report product order backlog, which is 30 months or younger. We ended the Q1 with backlog of approximately $538 million, which is 10.7% lower than prior year due to $51 million of order backlog that aged beyond 30 months within the quarter, mainly driven by customer installation delays. We had minimal cancellations, with only one unit canceled at $1.5 million and $3.5 million of FX and other adjustments. Our global commercial teams are focused on converting all orders regardless of time in the backlog to revenue. In Q1, this resulted in $5.9 million of orders converting to revenue within the quarter that had aged out previously. Our overall gross margin for the quarter was 35.9% compared to 36.8% in the prior year, which is a decrease of 90 basis points driven by unfavorable product mix, continued product cost inflation and service FX impact, which was partially offset by improved service margins, which signals that our pricing and cost discipline actions are taking shape in the service business. Operating expenses for the quarter were $36.8 million compared to $37.1 million in the prior year, showing good cost control as we continue to push our teams to drive cost discipline and be focused on return on investment. Operating income for the quarter was -$2.2 million compared to $2.4 million from prior year. Adjusted EBITDA for the quarter was $1.9 million compared to $5.4 million in the prior year, primarily due to lower revenue, which had an impact of $5.8 million in the top line and higher than expected FX impact, particularly in Japan and EMEA. The reconciliation between GAAP net income and adjusted EBITDA is described in our earnings release issued today. Turning to the balance sheet, total cash equivalents and short-term restricted cash amounted to $81 million compared to $88.7 million at the end of last quarter. Net accounts receivable were $77 million, down $17 million from last quarter as we had strong collection performance. Our net inventory balance was $153 million, up $26 million from prior year as we have built up our inventory to navigate through the ongoing supply chain challenges to fulfill our customer demand while ensuring healthy service stock levels. As Suzanne had mentioned earlier, we've activated our margin expansion plans that are focused on three critical areas. First area is pricing discipline to capture the right value for our innovations. We've aligned our commercial teams incentive plans to focus on capturing value and margin on incoming orders and have armed them with the tools to ensure the right profitability levels. Within the service organization, we're adjusting pricing and service contracts that are up for renewal and working on enhanced offerings to accommodate the needs of our customers, specifically in the areas of training and installation. The second area is to focus on reducing our overall product costs. Our sourcing organization is working with key suppliers to drive productivity on high-cost parts, and our engineering teams are focused on cost down projects, some in partnership with our JV partner. Additionally, the teams are focused on lowering our overall inbound and outbound logistics costs. We believe the reduced costs with these focused projects will also improve service margins in the coming quarters. Lastly, we are optimizing our operating expenses by ensuring we are getting the right return on the investments we are making in the business and are re-looking at all our direct and indirect spend and have identified key areas of opportunity. We are confident that taking these actions will get us back on track to pre-COVID margin levels. It is important to note that we recently amended our credit facility for Q2 and the remainder of FY 2023 to provide us more flexibility as we position ourselves for accelerated growth and investment while taking into account the headwinds of the current supply chain and foreign exchange environment. As both Suzanne and I had highlighted earlier, supply chain constraints and the headwinds associated with foreign exchange are the two biggest factors that have impacted our business performance in Q1. While we're doing everything we can to manage through the supply chain challenges and the current foreign exchange environment, FX impact alone is a $5.8 million negative impact to our top line compared to where exchange rates were last year in our non-U.S. markets. We are reiterating our full year guidance and will closely monitor the impact of macroeconomic trends, particularly in FX. Those are our key financial highlights. With that, I'd like to hand the call back to Suzanne. Thank you, Ali. In summary, I'd like to thank our teams for their unwavering support of our customers so they can provide the highest level of care to patients. We expect to continue to navigate the uncertainty of the macroeconomic and geopolitical conditions and reiterate guidance with expected revenue in the range of $447 million-$455 million and adjusted EBITDA in the range of $26 million-$30 million. We remain encouraged by the growing customer demand for Accuray technology and our robust product pipeline, and remain optimistic about market trends that favor Accuray technology and where we are positioned to win and take market share. As an organization, we are strengthening our fundamentals, advancing key growth catalysts in China, and creating new strategic partnerships like our partnership with GE Healthcare, all of which we believe will create long-term and meaningful value for patients, healthcare providers, employees, and our shareholders. I will now turn it back over to the operator for Q&A. We will now begin the question and answer session. To ask a question, you may press star then one on your telephone keypad. If you are using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star then two. Please limit yourself to two questions and you may rejoin the queue. At this time, we will pause momentarily to assemble our roster. The first question comes from Brooks O'Neil with Lake Street Capital. Please go ahead. Hi, this is Charlie Montang on for Brooks O'Neil. Just a couple quick questions from me. My first one is, when do you think the GE partnership can contribute to revenue? Do you think GE can help with hospital accounts, or do you need to integrate more products to generate meaningful revenue? Great. Thank you for the question. Yeah, we're very excited with our GE partnership. While it's early in the partnership, we do think in the short term that we'll be able to, you know, deliver a differentiated solution from precision diagnostics to precision treatment delivery. Together, I think we will have better visibility within the marketplace for our solutions. They obviously have a very strong commercial muscle, so we'll have the ability to see more of the market and greater customer access by leveraging the relationships that they have on the IDM level, on the government level. You know, in the short term, the you know key performance indicators that we're gonna be looking for is an increase in our order funnel growth, you know, the development of some key strategic reference sites, as well as just ongoing operating mechanisms. Long term, that should, we should start to see it in the financials. We should have an opportunity, I think, to look for more opportunities for synergy and joint solution development. Okay, great. Thank you. My last question is, you guys recently issued a press release with the submission of Tomo in China. When is the expected approval, and can you say when you expect initial orders to contribute to revenue? Yeah, thank you for the question. Yeah, we are very enthusiastic about the fact that things are starting to move in China. You know, this was an area that we were waiting to complete the submissions for our JV developed made in China type B product. So the fact that it is in the regulatory process is very exciting. Now, typical process there, and of course we can never predict a regulatory process, but it is probably 12 months, you know, historically. So what we would be expecting is 12 months from now, you know, we would have regulatory clearance, be able to take orders and, be able to be in a shipping position. Okay. Thank you. That's it for me, and congrats on a great quarter. Thank you. The next question comes from Josh Jennings with Cowen. Please go ahead. Hi. Good evening. Thanks for taking the questions. I wanted to just follow up with a multilayer question on the GE partnership. I wanted to better understand, I guess the vetting process for both Accuray and GE. Were you both looking for partners on the other side of the radiation oncology imaging fence? The reason I ask is it seems like a big validating signal that GE has decided to partner with Accuray. And then secondarily, one of the... I guess, competitive risks of this Siemens Varian combination clearly has been the potential for that entity to leapfrog a competition with the integration of advanced imaging platforms into their radiation oncology systems. Wanted to just better understand what's on the table. I know we talked a little bit about this at ASTRO, but, I mean, is it everything from MRI integration to improving the current ClearRT CT imaging to full diagnostic grade to functional imaging, and incorporating that into Accuray's platforms and/or or in terms of is that what we should be thinking about in terms of R&D collaborations and what they could produce longer term? Thanks for taking the questions. Thanks for the question, Josh. Just to kind of peel back the two parts of your question. You know, from GE Healthcare's standpoint, I think one of the strategies that they are looking at is to have a strategic area of care pathway that they are focused on oncology is one of those areas. They chose to partner with Accuray because we have an outstanding brand in the premium high performance market in terms of, you know, sub-millimeter precision. They see the clinical trend towards shorter duration treatments, and I think they see also an opportunity to shorten the time between diagnostics to treatment. You know, together here we are, two U.S. big companies that happen to be in Wisconsin, which is fantastic. We have the opportunity in the short term for a commercial collaboration. I think at a minimum, it is presenting a like one company, one face solution to our customers, for those customers that are building comprehensive cancer centers that are looking for both diagnostic imaging and treatment delivery. I think it also allows us to work with, you know, key opinion leaders, to see how we do shorten that time between treatment and from diagnostic to treatment. Longer term, I think there's opportunity for sure. They are a global leader in imaging. Imaging is becoming much more important in radiation therapy. That is why we're seeing such a great uptick from ClearRT to help with the planning. I don't think it'll ever do away completely with the SIM products, which is, you know, where diagnostic imaging and GE Healthcare products reside. Certainly I think there is an exchange of technology that as this commercial partnership progresses is an opportunity for synergy. Thanks again. The next question comes from Neil Chatterji with B. Riley. Please go ahead. Hi, guys. Thanks for taking the questions. You know, I guess congrats on getting the China JV registration submitted. Just curious, you know, on your view in terms of just any kind of geopolitical risk with China and, you know, any potential for that to slow down the regulatory process or you know, does having the domestic partner in CNNC kind of help shield you from that? Then I have one follow-up. Thank you. Thanks for the question, Neil. You know, obviously we're watching that very closely. I think the good news, and part of our competitive advantage, is that we do have a JV partner that's based in China that is a state-owned entity partially. You know, that we think gives us an advantage, you know, even in the midst of geopolitical conditions. You know, whether it'll help us, you know, in the regulatory submission process, unclear. We certainly will be watching that. I think it does give us the opportunity to hedge a little bit of what's happening. Got it. That's helpful color. You know, just in terms of the, you kind of talked about the partnership strategy and that, you know, kind of deepening the customer relationships. Just kind of curious if we can get maybe an update on the status of the Limbus AI partnership for automated contouring and whether that integrated offering remains on track for kind of an early 2023 launch and then what the expectations are for that. Yep. No, thank you for the question. Yeah, I think even coming out of ASTRO, the importance of being able to correct for changes that happen with the patient, is becoming very important, especially in these shorter duration treatments. You gotta get it right, because they're more powerful treatments over fewer fractionations, fewer appointments. We do have a partnership with RaySearch. RaySearch is a leader in treatment planning. They also have a very strong AI-backed algorithm for treatment planning. We have decided to put best of breed technologies together, you know, with them in order to bring this to market as quickly as possible. We did show both in our booth and in the RaySearch booth, a demonstration of this at ASTRO, and we are continuing the development. We are expecting, and again, we get regulatory approvals, so always difficult to judge, but we are expecting in the summertime of 2023 to have, you know, the ability hopefully to do a full market launch and be in a shipment position. Got it. I'm sorry, I was kind of asking specifically on Limbus AI. Oh, Limbus AI. Okay. Yeah. Limbus AI is another partnership that we have. Outside of what we are doing with RaySearch, we are also looking for an online adaptive capability on our own Precision Treatment Planning system. That will follow what we introduce with RaySearch. What we're trying to do is give our customers as many options as possible. If their preference is to go with RaySearch, then they have an option. If their preference is to stay with Accuray's Precision Treatment Planning, they also will have an online adaptive platform. I would say that is going to lag, and I will say probably anywhere from three to six months from the RaySearch introduction. Great. Thank you. The next question comes from Marie Thibault with BTIG. Please go ahead. Hey, good afternoon, Suzanne and Ali. This is Sam Eiber from BTIG. Thanks for taking the questions. Maybe just following up on some of these partnerships here, you know, multiple ones ongoing at the moment. I guess how significant of a differentiator could some of these be in driving competitive wins or faster trade-in and trade-ups? You know, is it something that could have the same impact that Synchrony and ClearRT had when those initially rolled out? Thank you for the question. Yeah, I think that the partnership that we have with C-RAD, for example, which we introduced at ASTRO, is now providing us with VitalHold, which is a breast cancer package. Now, I would say that that is very important to driving trade up and new systems, and it has been something that our customers have been asking for, especially on the Radixact. What it does is improve the versatility now of the Radixact System even more because breast cancer patients are about 25%-30% of a typical radiation therapy department. It's a very high percentage of the patients that come through the door. Being able to have this solution in addition to ClearRT and Synchrony is now really creating a true workhorse solution for patients that you know have simple cases to very complex. We're very encouraged by that. I think with every one of our partnerships, we're looking to have it add our ability to access more customers, increase the versatility of our system, and also deliver a differentiated value proposition. Got it. Really helpful there, Suzanne. Maybe I can just ask one more in the order environment. You know, another strong quarter here from a gross order standpoint. I guess maybe how that worked on a geography standpoint, you know, any areas of relative strength or weakness in the quarter year? Yep. Yeah. I mean, I can say in this quarter, you know, we saw the strength in orders really coming out of the U.S. and the APAC region, specifically China, which was very nice to see. You know, I would say we're watching, you know, region by region to sort of see the impact of some of the market dynamics. You know, I would say the only thing that we started to see a little bit in the U.S. is, from a revenue standpoint, it seems like there were some U.S. customers that were delayed by a quarter on some of the installations that they were seeing, primarily because they were seeing their own supply chain challenges during the installation as well as higher costs of construction. Again, it's not that demand, you know, stopped by any means. The demand is very strong, but I think that it was slowing some of the installation timeline. That's something that we're gonna continue to watch as we move forward to see you know, if it's a temporary solution. Now, I will say that there was some late-breaking news in the U.S. on the RO-APM, you know, which is, again, the new reimbursement model, and that looks like CMS is making a very strong statement that it is very much alive, and that it is going to happen. I do think that that may have some impact in the U.S. market. I'm excited to see that, but, you know, we'll wait to see how that plays out. Great. Thanks for taking the question. The next question comes from Jason Wittes with Loop Capital. Please go ahead. Hi, thanks for taking the questions. First off, you know, it's encouraging to hear the order rates picked up in China. Can you give us a sense of how much China is in the backlog and kind of what your outlook is in terms of when those might be placed and actually recognized as revenue? Yes. So we did say in the script and without giving, you know, specific numbers, but what is public information is, you know, who has been successful in getting through the bidding process. We know that there are 18 systems of customers that were holding Type A licenses, that once they get that approval to successfully get through the bidding process, they should, you know, we should be able to recognize that revenue over the next several quarters. You know, we don't have specific times at this point because it's sort of hot off the press, but that is a very strong sign of, you know, our ability to get clarity in terms of that revenue trajectory. Okay. That's helpful. You also mentioned I think on some of the OpEx focus comments two things. One, it sounds like you're putting in more. You're not actually discounting, but you are gonna put in more strict protocols for sales. Meaning I imagine there's some variance. It sounds like you might be tightening it. Am I reading that correctly? Then secondly, in terms of service margins, I think you also said that that's something you're gonna focus on. Will that be internal focus, internally focused, meaning just greater efficiencies and consolidation internally, or is that also related to pricing? Yep. It's a little bit of both, and I'll let Ali comment. Yeah, no, thanks for the question. I think number one, on the OpEx piece, you know, you'll see that, we actually had a pretty good finish on OpEx, and it's because we're continuing to drive a lot of cost discipline with our teams. You know, as you know, we are in a pretty volatile macroeconomic environment, and so we just wanna make sure that, you know, we're scrubbing all of our costs, both direct and indirect, to make sure that anything that we're making investment in, has the right return. So that's it on the OpEx side. Then on the service margin side, you know, it's a little bit of both, Jason. I think on the top line, we are making sure that our offerings are getting the right pricing. We're also intending on introducing a couple of new offerings, which we think will help us from a margin standpoint. More importantly, you know, on the service side, there is you know, quite a bit of cost. We're just making sure that we are being efficient with all of that cost, specifically when it comes to part consumption and then also taking a look at our field engineering utilization. Okay, great. That's helpful as well. Maybe just a quick follow-up on the GE relationship. I guess I wasn't sure, it might have been stated before in the release, but is there also R&D collaboration or is this strictly focused on distribution? At this point, it's a commercial agreement that's primarily in the short term focused on distribution. Got it. Thanks a lot. I'll come back to you. This concludes our question-and-answer session. I would like to turn the conference back over to Suzanne Winter for any closing remarks. I wanna thank everyone for your attendance on the call. This concludes our earnings call, and we look forward to speaking with you all again in January for our fiscal 2023 Q2 earnings release. The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.